| Private Placement / Financing Transactions
Cellanome: The company raised $150 million of Series B venture funding from Premji Invest (US) and undisclosed investors on January 29, 2024, putting the company’s pre-money valuation at $375 million. The company is a developer of a unique multi-omics platform designed to measure biology at an unprecedented resolution and scale.
Cour: The company raised $105 million of Series A venture funding in a deal led by Lumira Ventures and Alpha Wave Global on January 30, 2024, putting the company’s pre-money valuation at $65 million. Roche Venture Fund, Pfizer Ventures, Bristol-Myers Squibb, Angelini Ventures, T1D Fund and Chimera Capital also participated in the round. The company is a developer of an immune-modifying platform intended to achieve antigen specific tolerance for immune-mediated disease.
Cohere Health: The company raised $50 million of venture funding in a deal led by Deerfield Management on February 1, 2024. Flare Capital Partners, Define Ventures, Polaris Partners, and Longitude Capital also participated in the round. The company is an operator of a clinical intelligence company intended to provide prior authorization by aligning physicians and health plans.
Halia Therapeutics: The company raised $30 million of Series C venture funding in a deal led by Todd Pedersen on January 31, 2024, putting the company’s pre-money valuation at $175 million. The company is a developer of novel therapies designed to improve the lives of patients with inflammatory disorders and neurological diseases.
Entactbio: The company raised $39.9 million of Series A-2 venture funding from undisclosed investors on January 31, 2024, putting the company’s pre-money valuation at $36 million. The company is a developer of a biotechnology research company designed to enhance the function of beneficial proteins.
Enterprise Therapeutics: The company raised GBP 26 million of Series B venture funding in a deal led by Panakes Partners on January 30, 2024. Novartis Venture Fund, IP Group, Forbion, Epidarex Capital and Versant Ventures also participated in the round. The company is an operator of a drug discovery and development firm intended to develop novel therapies for the treatment of respiratory diseases.
Ablative Solutions: The company raised $29.3 million of venture funding in the form of convertible debt from undisclosed investors on January 30, 2024. The company is an operator of a clinical-stage medical device company intended to address the significant unmet clinical need for systemic hypertension.
Artera: The company raised $20 million of venture funding from Prosperity7 Ventures, EDBI, and Wilson Sonsini Goodrich & Rosati on February 1, 2024. The Trium Group, Walden Catalyst, Navin Chaddha, Rajiv Khemani, Elliott Tan, Andrew Tan, and other undisclosed investors also participated in the round. The company is a developer of AI-enabled predictive and prognostic cancer tests intended to identify patients who will benefit from therapy intensification.
ResistanceBio: The company raised $12.8 million of venture funding through a combination of equity and convertible debt from undisclosed investors on January 31, 2024. The company is a developer of oncology drugs and environmental cellular reprogramming (ENCER) cancer models designed to fight treatment-resistant cancer.
Epicore Biosystems: The company raised $11.5 million of Series A1 venture funding in a deal led by Denka Company and Pegasus Tech Ventures on February 1, 2024, putting the company’s pre-money valuation at $73 million. The company is a developer of a wearable microfluidic sensor technology designed to improve health and drive athletic performance.
Seranova Bio: The company raised $10 million of venture funding from undisclosed investors on February 4, 2024. The company is an operator of a biotechnology business intended to develop therapeutics to treat autoimmune disease.
Lirio: The company raised $3.2 million of venture funding from undisclosed investors on January 30, 2024. The company is a developer of a behavior change AI platform.
KromaTiD: The company raised $2 million of venture funding from undisclosed investors on January 31, 2024. The company is a developer of next-gen cytogenetic products focused on discovering, detecting and diagnosing genomic rearrangements in the areas of oncology and rare diseases.
Moximed: The company raised an undisclosed amount of venture funding from Warren Point Capital in February 2024. The company is a developer of unicompartmental load absorber implants intended to improve the standard of care for patients with osteoarthritis.
Trially: The company raised an undisclosed amount of venture funding from Redbud VC in February 2024. The company is a developer of an AI-powered clinical trial recruitment platform designed to streamline clinical research and catalyze advanced therapies.
Triple Ring Technologies: The company received an undisclosed amount of development capital from 1315 Capital on February 1, 2024. The company is a provider of incubation services intended to assist life science and medical device companies.
Zakipoint Health: The company raised an undisclosed amount of venture funding from RevUp Capital, James Kalustian and Eric Beyer on February 1, 2024. Ramesh Motwane, Paul Jaggi, Adam Ghander, Praveen Tailam, Roopa Unnikrishnan, Thomas Craig and Ansley Capital Group also participated in the round. The company is a developer of a cloud-based healthcare analytical tool created to help customers understand healthcare costs.
Terran Biosciences: The company raised an undisclosed amount of Series B venture funding from Brkfst Club in February 2024. The company is an operator of a biotech platform company intended to develop a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.
|
